345 related articles for article (PubMed ID: 26388534)
21. Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial.
Mir F; Quadri F; Mach O; Ahmed I; Bhatti Z; Khan A; Rehman NU; Durry E; Salama M; Oberste SM; Weldon WC; Sutter RW; Zaidi AK
Lancet Infect Dis; 2015 Aug; 15(8):889-97. PubMed ID: 26093979
[TBL] [Abstract][Full Text] [Related]
22. Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?
Resik S; Tejeda A; Mach O; Fonseca M; Diaz M; Alemany N; Heng Hung L; Aleman Y; Mesa I; Garcia G; Sutter RW
Clin Infect Dis; 2018 Oct; 67(suppl_1):S51-S56. PubMed ID: 30376088
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity of sequential poliovirus vaccination schedules with different strains of poliomyelitis vaccines in Chongqing, China: a cross-sectional survey.
Xu J; Wang Q; Kuang S; Rong R; Zhang Y; Fu X; Tang W
Hum Vaccin Immunother; 2021 Jul; 17(7):2125-2131. PubMed ID: 33759702
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
[TBL] [Abstract][Full Text] [Related]
25. Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America.
Lopez-Medina E; Melgar M; Gaensbauer JT; Bandyopadhyay AS; Borate BR; Weldon WC; Rüttimann R; Ward J; Clemens R; Asturias EJ
Vaccine; 2017 Jun; 35(28):3591-3597. PubMed ID: 28455172
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review.
Bandyopadhyay AS; Modlin JF; Wenger J; Gast C
Clin Infect Dis; 2018 Oct; 67(suppl_1):S35-S41. PubMed ID: 30376081
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial.
Wilkinson AL; Zaman K; Hoque M; Estivariz CF; Burns CC; Konopka-Anstadt JL; Mainou BA; Kovacs SD; An Q; Lickness JS; Yunus M; Snider CJ; Zhang Y; Coffee E; Abid T; Wassilak SGF; Pallansch MA; Oberste MS; Vertefeuille JF; Anand A
Lancet Infect Dis; 2023 Sep; 23(9):1062-1071. PubMed ID: 37178706
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: A randomized, controlled, open-label, phase IV clinical trial in China.
Yan S; Chen H; Zhang Z; Chang S; Xiao Y; Luo L; Zhang Z; Sun L; Chen X; Yang Y; Shi X; Guo Y; Sun Y; Li H; Li N; Han S; Ma M; Yang X
Vaccine; 2020 Sep; 38(40):6274-6279. PubMed ID: 32747216
[TBL] [Abstract][Full Text] [Related]
29. Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis.
Macklin GR; Grassly NC; Sutter RW; Mach O; Bandyopadhyay AS; Edmunds WJ; O'Reilly KM
Lancet Infect Dis; 2019 Oct; 19(10):1121-1128. PubMed ID: 31350192
[TBL] [Abstract][Full Text] [Related]
30. Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants.
Brickley EB; Wieland-Alter W; Connor RI; Ackerman ME; Boesch AW; Arita M; Weldon WC; O'Ryan MG; Bandyopadhyay AS; Wright PF
Clin Infect Dis; 2018 Oct; 67(suppl_1):S42-S50. PubMed ID: 30376086
[TBL] [Abstract][Full Text] [Related]
31. Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016.
Immunization Systems Management Group of the Global Polio Eradication Initiative
MMWR Morb Mortal Wkly Rep; 2015 Jul; 64(25):699-702. PubMed ID: 26135591
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.
Snider CJ; Zaman K; Estivariz CF; Yunus M; Weldon WC; Wannemuehler KA; Oberste MS; Pallansch MA; Wassilak SG; Bari TIA; Anand A
Lancet; 2019 Jun; 393(10191):2624-2634. PubMed ID: 31104832
[TBL] [Abstract][Full Text] [Related]
33. Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame.
Gaensbauer JT; Gast C; Bandyopadhyay AS; O'Ryan M; Saez-Llorens X; Rivera L; Lopez-Medina E; Melgar M; Weldon WC; Oberste MS; Rüttimann R; Clemens R; Asturias EJ
Clin Infect Dis; 2018 Oct; 67(suppl_1):S57-S65. PubMed ID: 30376095
[TBL] [Abstract][Full Text] [Related]
34. Reduced mucosal immunity to poliovirus after cessation of trivalent oral polio vaccine.
Zhao T; Li J; Shi H; Ye H; Ma R; Fu Y; Liu X; Li G; Yang X; Zhao Z; Yang J
Hum Vaccin Immunother; 2021 Aug; 17(8):2560-2567. PubMed ID: 33848232
[TBL] [Abstract][Full Text] [Related]
35. Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States.
Marin M; Patel M; Oberste S; Pallansch MA
MMWR Morb Mortal Wkly Rep; 2017 Jan; 66(1):23-25. PubMed ID: 28081056
[TBL] [Abstract][Full Text] [Related]
36. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
[TBL] [Abstract][Full Text] [Related]
37. India's Preparedness for Introduction of IPV and Switch from tOPV to bOPV.
Haldar P; Agrawal P
Indian Pediatr; 2016 Aug; 53 Suppl 1():S44-S49. PubMed ID: 27771639
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity of a combined schedule of trivalent oral and inactivated polio vaccines in South African infants.
Moonsamy S; Suchard MS; Madhi SA
Expert Rev Vaccines; 2019 Jul; 18(7):751-754. PubMed ID: 31194605
[No Abstract] [Full Text] [Related]
39.
Zhao T; Mo Z; Ying Z; Huang T; Che Y; Li G; Yang X; Sun M; Jiang L; Shi L; Ye H; Zhao Z; Liu X; Li J; Li Y; Li R; Jiang R; Wang J; Fu Y; Ma R; Shi H; Yang H; Li C; Yang J; Li Q
Ann Transl Med; 2021 Feb; 9(3):253. PubMed ID: 33708880
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: A systematic review and meta-analysis.
Tang G; Yin W; Cao Y; Tan L; Wu S; Cao Y; Fu X; Yan J; Jiang X
Hum Vaccin Immunother; 2018; 14(11):2636-2643. PubMed ID: 29985751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
